Short answer
UNITED THERAPEUTICS Corp (UTHR) filed an 8-K current report with the SEC on October 22, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). $2.0 billion share repurchase authorization approved, signaling substantial capital return to shareholders.
UNITED THERAPEUTICS Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- $2.0 billion share repurchase authorization approved, signaling substantial capital return to shareholders
- Program runs through October 21, 2027, providing flexibility on repurchase timing
- Potential share-count reduction and enhanced per-share metrics, depending on execution
- Exhibit 99.1 contains the company’s announcement and additional program details
Item EX-99.1 · Exhibit EX-99.1
- New $2 billion repurchase authorization available through October 21, 2027
- Capital-return capacity signals management confidence and prioritizes buybacks alongside long-term investment
- Purchases may use ASRs, open-market or private transactions, with no minimum commitment
- Existing September 2026 ASR remains outstanding and will not reduce the new authorization
- Buyback execution remains discretionary, dependent on market conditions and alternative capital uses
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other UNITED THERAPEUTICS Corp 8-K filings
Get the next UTHR 8-K as it lands
Follow UTHR for push alerts, or ask the research agent what this filing means.